DHX9 and tuberculosis: Combinations of inhibitors targeting either cytochrome bc1-aa3 oxidase and cytochrome bd oxidase or NDH-2 and NHD-1 will be required to effectively inhibit the respiratory chain of Mtb. In this context, our work further unveiled genetic and chemical–genetic interactions which could be exploited to improve TB chemotherapy, namely the interactions between cytochrome bc1-aa3 oxidase and NDH-1, NDH-2 and ATP synthase, and NDH-2 and cytochrome bd oxidase.